Scientific Advisory Board
Dr. Uri Lopatin
|
Dr. Lopatin is a serial biotech entrepreneur with experiences across executive, clinical and translational science positions across biotech and pharmaceutical companies, including Schering-Plough, Roche, Gilead Sciences. He was co-founder of Assembly Pharmaceuticals (NASDAQ: ASMB) functioning as both Chief Medical Officer and Vice President of Research, and was the Founder, CEO and President of Pardes Biosciences (NASDAQ:PRDS). Between Found ASMB and PRDS, Dr. Lopatin spent time with Y Combinator, as a visiting partner focused on early-stage biotech. Uri has published and patented broadly in virology and immunology. Uri received a BA in Biology from Cornell University and MD degree at the University of Medicine and Dentistry of New Jersey – New Jersey Medical School. He completed his residency at New York University Medical Center, internship at the University of Washington, and fellowship training in Infectious Disease at the National Institutes of Health.
|
Shape Divider - Style waves
Olivia Merkel
|
Olivia Merkel has been a Professor of Drug Delivery at LMU Munich since 2015 and Chair since 2022. She is a Registered Pharmacist, received a MS (2006) and a PhD (2009) in Pharmaceutical Technology as well as numerous awards, including an ERC Starting Grant, ERC Proof-of-Concept Grant, the APV Research Award and the Carl-Wilhelm-Scheele-Award. Merkel is the author of over 100 articles and book chapters. She served as NIH reviewer from 2014-2015, SNF reviewer from 2018-2022, is an Editorial Board member for JCR, EJPB, Molecular Pharmaceutics and other journals, was the President of the German Controlled Release Society in 2020 and the Chair of the CRS Focus Group on Transdermal and Mucosal Delivery from 2020-2022. Her research focuses mainly on RNA formulation and pulmonary delivery for the treatment of a variety of lung diseases.
|
|
Shape Divider - Style waves
Shape Divider - Style waves
Neville Sanjana
|
Neville Sanjana, PhD, is a Core Faculty Member at the New York Genome Center and an Associate Professor in the Departments of Biology and of Neuroscience and Physiology at New York University. As a bioengineer, Dr. Sanjana has developed high-throughput genome engineering tools to understand the impact of genetic changes on cancer evolution, viral pathogenesis, drug resistance and the nervous system.
Dr. Sanjana is a recipient of the Presidential Early Career Award for Engineers and Scientists, AAAS Wachtel Prize for Cancer Research, the NIH’s New Innovator Award, the Cancer Research Institute Technology Impact Award, the DARPA Young Faculty Award, the Kimmel Scholar Award, the MRA Young Investigator Award, and also is the Leichtung Family Investigator of the Brain and Behavior Foundation. Dr. Sanjana holds a PhD in Brain and Cognitive Sciences from MIT, a BS in Symbolic Systems and a BA in English from Stanford University. |